Omiganan

Summary

Omiganan is an investigational, cationic antimicrobial peptide derived from indolicidin. It is formulated for topical use and has been explored for acne, nasal decolonisation of Staphylococcus aureus, and atopic dermatitis. Early studies suggest it can modulate skin microbiota and exhibit antimicrobial activity, but its clinical benefit remains uncertain.

Mechanism of Action

Omiganan is a synthetic indolicidin analogue that exerts its antimicrobial effect primarily by binding to and disrupting bacterial cell membranes, leading to rapid cell death. In addition, a dermatology review identifies omiganan pentahydrochloride as a stearoyl‑CoA desaturase inhibitor, potentially altering lipid synthesis pathways that contribute to sebocyte activity in acne. These actions together may reduce pathogenic bacteria and modulate skin‑related signaling cascades.

What the Research Shows

A 2019 dermatology review listed omiganan as a stearoyl‑CoA desaturase inhibitor under investigation for acne, though no clinical efficacy data were presented. A 2016 infection‑control review noted omiganan pentahydrochloride as a candidate nasal decolonisation agent, but highlighted the need for large trials. Two phase‑II trials in atopic dermatitis (2020 and 2022) examined topical gels (1‑2.5% w/w) applied for 28 days. The 2020 study reported modest improvements in SCORAD scores and a shift toward a healthier skin microbiome at the higher dose, while the 2022 study confirmed reduction of Staphylococcus aureus and restoration of microbial diversity but found no significant clinical symptom benefit. A 2023 review of stapled antimicrobial peptides cited omiganan among agents in clinical development, underscoring its investigational status.

Reported Benefits

Omiganan demonstrates broad‑spectrum antimicrobial activity, notably reducing Staphylococcus aureus colonisation on the skin. In atopic dermatitis, it can restore microbial diversity and shift dysbiotic communities toward a healthier profile. One small trial observed modest improvements in objective disease scores at a 2.5% dose, suggesting potential anti‑inflammatory effects linked to microbiome modulation.

Limitations of the Evidence

Evidence for omiganan is limited to early‑phase, small‑sample studies. Clinical efficacy in atopic dermatitis was inconsistent, with one trial showing no symptom improvement despite microbiome changes. No human data support its use for acne or nasal decolonisation, and larger, controlled trials are required to confirm safety and therapeutic benefit. Its activity as a stearoyl‑CoA desaturase inhibitor remains theoretical.

Safety Considerations

Both phase‑II atopic dermatitis trials reported that topical omiganan was well tolerated, with no serious adverse events noted over the 28‑day treatment period. Reported side‑effects were minimal and comparable to vehicle gel. However, safety data are confined to short‑term topical exposure in limited populations; long‑term or systemic safety remains uncharacterised.

How It Is Administered

Omiganan is investigated as a topical gel applied to affected skin lesions once or twice daily for up to 28 days, using concentrations ranging from 1 % to 2.5 % (w/w). Formulations are aqueous‑based gels. The peptide has also been discussed as a nasal spray for decolonisation, though such use remains experimental.

Routes of Administration

Goals & Uses

• Prevention of catheter‑related bloodstream infectionsInfection ProphylaxisModerate
• Treatment of inflammatory rosaceaDermatologyModerate
• Treatment of mild to moderate acne vulgarisDermatologyModerate
• Broad-spectrum antimicrobial activity (gram-positive, gram-negative, fungi)Anti InfectiveModerate
• Treatment of acne vulgarisDermatologyLow
• Prevention of catheter-related bloodstream infectionsAnti Infective / ProphylaxisModerate

Contraindications

• Application to open wounds or mucous membranes (outside studied indications)SafetyModerate
• Hypersensitivity to Omiganan or formulation componentsAllergyHigh
• Known hypersensitivity to omiganan or related peptidesAllergyHigh

Adverse Effects

• Local skin irritationDermatologicalCommon
• PruritusDermatologicUncommonItching
• Contact dermatitisDermatologicalUncommon
• Application site irritationLocal/dermatologicalCommon
• Systemic toxicitySystemicRare
• erythemaLocalCommon

Drug Interactions

• none identifiedLow
• Other topical antimicrobialsLow

Population Constraints

• PregnancyReproductive SafetyRelative
• Pediatric patientsAgeRelative
• Pediatrics (<12 years)AgeRelative
• Pregnant or lactating womenReproductiveRelative
• Patients with compromised skin barrierDisease RelatedRelative

Regulatory Status

• European UnionInvestigationalClinical trials ongoing; not authorized
• United StatesInvestigationalUnder IND for catheter lock and acne studies
• United KingdomInvestigationalNo marketing authorization

No regulatory approval as of 2024; Phase III trials completed but not submitted for marketing.

Evidence & Sources

• From pathogenesis of acne vulgaris to anti-acne agents
  Journal ArticleModerateCong TX, et al.2019-01-01T00:00:00.000000Z
• Rational design of stapled antimicrobial peptides
  Journal ArticleModerateYou Y, et al.2023-01-01T00:00:00.000000Z
• Decolonization in Prevention of Health Care-Associated Infections
  Journal ArticleModerateSeptimus EJ, Schweizer ML2016-01-01T00:00:00.000000Z
• Treatment Interventions for Usual-Type Vulvar Intraepithelial Neoplasia: A Systematic Review and Meta-analysis
  Journal ArticleHighSimões AC, et al.2025-01-01T00:00:00.000000Z
• Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo-Controlled, Phase II Trial
  Journal ArticleModerateNiemeyer-van der Kolk T, et al.2020-01-01T00:00:00.000000Z
• Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial
  Journal ArticleModerateNiemeyer-van der Kolk T, et al.2022-01-01T00:00:00.000000Z

Frequently Asked Questions